|
|
 |
|
Viewing report
|
|
|
|
Acute Lymphocytic Leukemia - Unmet Needs in Adult and Pediatric Populations Drive Recent Market Developments
Decision Resources, Inc., June 2010, Pages: 44
The heterogeneity of acute lymphocytic leukemia (ALL) makes a universal treatment for the disease extremely difficult to discover and develop: because pediatric and adult ALL are biologically and clinically distinct, treatments that work for one group of patients will not necessarily work for others. For example, effective pediatric ALL treatments have not yielded the same results in adult ALL patients. This treatment gap is compounded by lack of understanding of the etiology of the disease.
Although recent drug approvals in ALL will help certain niche populations of patients, until the causes of the disease are better understood, treatments better tailored to adult ALL patients will be lacking.
Questions answered in this report:
- ALL is the most common pediatric cancer. How common is the disease in non-pediatric populations? What is the incidence of ALL in the overall population?
- Despite successes in treating pediatric ALL, effective adult ALL treatments are still lacking. What are some of the underlying causes of the diffi culty in treating adult ALL?
- ALL treatment is considered the most complicated of all hematological cancer treatments. What factors make ALL treatment so complex?
- The clinical ALL pipeline is less robust than pipelines for other acute leukemias, such as acute myelogenous leukemia (AML). What are the reasons for the low number of ALL pipeline agents? What are the leading agents in development?
- Despite the diffi culties in treating ALL, four therapies have recently received marketing approval in this indication. What are these four therapies? For which ALL populations did they receive marketing approval?
Scope of the report:
- Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
- Primary research: Survey of 50 U.S. hematological oncologists, conducted in January 2010.
- Epidemiology: Diagnosed incident ALL cases; treatable pool of ALL cases; forecast of cases from 2008-2018.
- Prognostic indicators: Age at diagnosis; white blood cell count at presentation; immunophenotype; cytogenetic abnormalities; early response to therapy and minimal residual disease (MRD); in vitro response to chemotherapy.
- Emerging therapies: Phase II: 5 drugs; Phase III: 3 drugs. Identifi cation of 2 select Phase I and Phase I/II drugs.
Key terms for this report:
Acute lymphocytic leukemia (AML), Acute lymphoblastic leukemia (ALL), Adult leukemia, Arranon, Biomarkers, Chronic therapy, Clolar, Gleevec, Hematological oncology, Pediatric leukemia, Targeted therapies
Customers who bought this item also bought
Can New Therapies Unseat Traditional Chemotherapy Regimens in Acute Myelogenous Leukemia?
Leukemias: Principles and Practice of Therapy
Leukemia Therapeutics Market (2010-2020) (Acute/Chronic lymphocytic leukemia & Acute/Chronic myeloid leukemia) Pipeline forecast & Market forecast in G8 countries
Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy
Pipeline Insight: Leukemias Underserved patient populations offer potential for market growth
Chronic Lymphocytic Leukemia: Off-Label Prescribing Drives Market Growth
Current Treatments, Unmet Needs, and Opportunities in Treating Pediatric Crohn’s Disease
Personalized Medicine - Scientific and Commercial Aspects
Acute Lymphocytic Leukemia (ALL) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Problem Solving in Haematology
|
|
|
|
